



#28/22

PATENT 04/07/8

Docket No. 232.00010101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Pulst et al.) Group Art Unit: 1818
Serial No.: 08/727,084) Examiner: M. Allen
Filed: October 8, 1996)
For: NUCLEIC ACID ENCODING SPINOCEREBELLAR ATAXIA-2 AND
PRODUCTS RELATED THERETO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington D.C. 20231

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Consideration of each of the documents listed on the attached 1449 form is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form, marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Applicants have included the fee of \$240 under 37 CFR §§1.97(c) and 1.17(p).
Please charge any additional fees or credit any overpayment to Account No. 13-4895.

When the Examiner takes up the present application, consideration of these documents is respectfully requested. The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on this 23 day of September, 1998.

Ann M. Muetting
Ann M. Muetting

Date

September 23, 1998

Respectfully submitted,
Stefan M. Pulst
By their Representatives,
Muetting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
(612)305-1220

By:

Ann M. Muetting
Ann M. Muetting

Reg. No. 33, 977

Direct Dial (612)305-1217